期刊文献+

加替沙星治疗急性细菌性呼吸道和泌尿道感染 被引量:6

Acute Bacterial Respiratory and Urinary Tract Infection Treating by Gatifloxacin
下载PDF
导出
摘要 目的 :评价国产加替沙星注射液治疗急性细菌性呼吸道和泌尿道感染的有效性与安全性。方法 :采用区组随机、平行对照、多中心研究设计 ,加替沙星注射液与左氧氟沙星注射液均为 2 0 0mg ,ivd ,q12h ,疗程 5~ 14d。 结果 :本项试验实际入组 4 9例 ,其中加替沙星组 2 7例 ,左氧氟沙星组 2 2例 ,治疗结果加替沙星与左氧氟沙星组临床有效率分别为 96 .30 %与95 .4 5 % ,细菌清除率分别为 95 .2 4 %与 10 0 % ,不良反应发生率分别为 7.4 1%与 4 .5 5 % ,上述结果均无统计学差异。结论 :加替沙星与左氧氟沙星在治疗临床常见的敏感细菌引起的呼吸道、泌尿道感染均是安全、有效的抗菌药物。 Objective: To evaluate the efficacy and safety of domestic gatifloxacin injection in the treatment of acute bacterial respiratory and urinary tract infection.Method: A multi center randomized controlled clinical trial was conducted to compare the gatifloxacin and levofloxacin in the treatment of acute bacterial respiratory and urinary tract infection. The doses of both agents were 200 mg q12h by intravenous infusion which sustained for 30 to 60 min. The duration of therapy was 5 to 14 days in both groups.Result: Forty nine patients, were enrolled in this study, were divided into gatifloxacin group ( n =27) or levofloxacin group ( n =22). The overall effective rates and bacterial clearance rates were 96.30% and 95.24% in gatifloxacin group, 95.45% and 100% in levofloxacin group, respectively, the frequency of adverse drug reactions in both groups were 7.41% and 4.55% , respectively. No statistical significances were found in above data.Conclusion: Gatifloxacin and levofloxacin were effective and safe in the treatment of acute bacterial respiratory and urinary tract infection.
机构地区 北京天坛医院
出处 《中国药师》 CAS 2004年第12期951-953,共3页 China Pharmacist
关键词 加替沙星 左氧氟沙星 随机对照试验 Gatifloxacin Levofloxacin Randomized controlled clinical trial
  • 相关文献

参考文献9

  • 1Jones RN, Beath ML, Pfaller MA, et al. Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America[J]. Diagn Microbiol Infect Dis, 1998,32(3)
  • 2Vostrov SN, Kononenko OV, Lubenko IY, et al. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio[J]. Antimicrob Agents Che
  • 3Wise R, Andrews JM, Ashby JP, et al. A study to determine the pharmacokinetics and inflamatory fluid penetration of gatifloxacin following a single oral dose[J]. J antimicrob. Chemother, 1999,44(5):701-704
  • 4Saravolatz L, Manzor O, Check C, et al. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae[J]. J Antimicrob Chemother, 2001,47(6):875-877
  • 5Huczko E, Conetta B, Bonner D, et al. Susceptibility of bacterial isolates to gatifloxacin and ciprofloxacin from clinical trials 1997-1998[J]. Int J Antimicrob Agents, 2000,16(4):401-405
  • 6McCloskey L, Moore T, Niconovich N, et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA[J]. J Antimicrob Chemother, 2000,45 Suppl 1:13-21
  • 7Nakashima M, Uematsu T, Kosuge K, et al. Single and multiple dose pharmacokinetics of AM-1155, a new 6-fluro-8-methoxy quinolone, in humans[J]. Antimicrob. Agents and Chemotherapy, 1995,39(12):2635-2640
  • 8Lober S, Ziege S, Ran M, et al. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium[J]. Antimicrob. Agents and Chemotherapy, 1999,43(5):1067-1071
  • 9Perry CM, Barman Balfour JA, Lamb HM. Gatifloxacin[J]. Drugs, 1999,58(4):683-696

同被引文献81

引证文献6

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部